HYPNOTIC AND ANTI-EPILEPTIC EFFECTS OF CANNABIDIOL
HYPNOTIC AND ANTI-EPILEPTIC EFFECTS OF CANNABIDIOL
复制标题
DOI：
10.1002/j.1552-4604.1981.tb02622.x
复制
发表时间：
1981-01-01
影响因子：
2.9
通讯作者：
CUNHA, JM
中科院分区：
文献类型：
--
作者：
CARLINI, EA;CUNHA, JM
从1972年至今，作者在实验室对健康志愿者、失眠症患者和癫痫患者进行了大麻二酚（CBD）的临床试验。急性剂量为10至600毫克的大麻二酚和慢性剂量为10毫克连续20天或3毫克/公斤/天连续30天的大麻二酚不会引起提示精神药物或毒性作用的心理或生理症状；然而，有几名志愿者抱怨自己嗜睡。补充实验室检查（心电图、血压、血液和尿液分析）未发现毒性迹象。在15名失眠症志愿者中，将40、80和160毫克的大麻二酚剂量与安慰剂和5毫克硝西泮进行了比较。服用160毫克大麻二酚的受试者报告睡眠时间明显多于服用安慰剂的受试者；志愿者还报告说，与安慰剂相比，服用三剂大麻二酚的志愿者回忆梦境的次数明显减少。15例继发性全身性癫痫患者对已知抗癫痫药物难治，每天接受200至300毫克大麻二酚或安慰剂治疗长达4.5个月。在接受大麻二酚治疗的8名癫痫患者中，有7人的病情有所改善，而只有1名安慰剂患者的病情有所改善。
Clinical trials with cannabidiol (CBD) in healthy volunteers, insomniacs, and epileptic patients conducted in the authors' laboratory from 1972 up to the present are reviewed. Acute doses of cannabidiol ranging from 10 to 600 mg and chronic administration of 10 mg for 20 days or 3 mg/kg/day for 30 days did not induce psychologic or physical symptoms suggestive of psychotropic or toxic effects; however, several volunteers complained of somnolence. Complementary laboratory tests (EKG, blood pressure, and blood and urine analysis) revealed no sign of toxicity. Doses of 40, 80, and 160 mg cannabidiol were compared to placebo and 5 mg nitrazepam in 15 insomniac volunteers. Subjects receiving 160 mg cannabidiol reported having slept significantly more than those receiving placebo; the volunteers also reported significantly less dream recall with the three doses of cannabidiol than with placebo. Fifteen patients suffering from secondary generalized epilepsy refractory to known antiepileptic drugs received either 200 to 300 mg cannabidiol daily or placebo for as long as 4.5 months. Seven out of the eight epileptics receiving cannabidiol had improvement of their disease state, whereas only one placebo patient improved.